Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Charles River (CRL) to $200 from$190 and keeps an Outperform rating on the shares. The firm’s survey work points to a positive outlook for preclinical CROs, with rising budgets and declining cancellations, along with suggesting stable demand for discovery and toxicology services into 2025 and 2026, the analyst tells investors in a note on the group. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! U ...